Clinical Relevance of uPA, uPAR, PAI 1 and PAI 2 Tissue Expression and Plasma PAI 1 Level in Colorectal Carcinoma Patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00055477" target="_blank" >RIV/00216224:14110/11:00055477 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.5754/hge10232" target="_blank" >http://dx.doi.org/10.5754/hge10232</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5754/hge10232" target="_blank" >10.5754/hge10232</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Clinical Relevance of uPA, uPAR, PAI 1 and PAI 2 Tissue Expression and Plasma PAI 1 Level in Colorectal Carcinoma Patients

Popis výsledku v původním jazyce

Urokinase (uPA) is a serine protease, which together with uPAR, tPA, PAI 1 and PAI 2 forms the plasminogen activator system, a component of metastatic cascade contributing to the invasive growth and angiogenesis of malignant tumours. Methodology: Both preceding therapy and after 6-8 weeks of the treatment, plasma PAI 1 levels (photometric microplate method on the ELISA) and uPA, uPAR, PAI 1 and PAI 2 tissue expression (immunohistochemical reaction) were analysed from 80 colorectal carcinoma patients. Results: Analysis showed higher pre-treatment plasma levels of PAI 1 in patients with advanced tumours, which decreased after surgery or the start of therapy (p=0.004); Patients with higher plasma level PAI 1 before (0.013) and after therapy (0.004) had significantly shorter survival. There was a higher expression of uPA (p&lt;0.001), uPAR (p&lt;0.001), PAI 1 (p=0.042) and PAI 2 (p&lt;0.001) in advanced colorectal carcinoma. A relationship between PAI 2 (p=0.010) and uPAR (p=0.

Název v anglickém jazyce

Clinical Relevance of uPA, uPAR, PAI 1 and PAI 2 Tissue Expression and Plasma PAI 1 Level in Colorectal Carcinoma Patients

Popis výsledku anglicky

Urokinase (uPA) is a serine protease, which together with uPAR, tPA, PAI 1 and PAI 2 forms the plasminogen activator system, a component of metastatic cascade contributing to the invasive growth and angiogenesis of malignant tumours. Methodology: Both preceding therapy and after 6-8 weeks of the treatment, plasma PAI 1 levels (photometric microplate method on the ELISA) and uPA, uPAR, PAI 1 and PAI 2 tissue expression (immunohistochemical reaction) were analysed from 80 colorectal carcinoma patients. Results: Analysis showed higher pre-treatment plasma levels of PAI 1 in patients with advanced tumours, which decreased after surgery or the start of therapy (p=0.004); Patients with higher plasma level PAI 1 before (0.013) and after therapy (0.004) had significantly shorter survival. There was a higher expression of uPA (p&lt;0.001), uPAR (p&lt;0.001), PAI 1 (p=0.042) and PAI 2 (p&lt;0.001) in advanced colorectal carcinoma. A relationship between PAI 2 (p=0.010) and uPAR (p=0.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FP - Ostatní lékařské obory

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Hepatogastroenterology

ISSN

0172-6390

e-ISSN

—

Svazek periodika

58

Číslo periodika v rámci svazku

112

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

8

Strana od-do

1918-1925

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—